Shilpa Medicare Limited is recalling over 53,000 units of several prescription medications, including Busulfan, Azacitidine, Imatinib Mesylate, and Docetaxel, due to deviations from Current Good Manufacturing Practice (CGMP) standards. These drugs are used to treat various types of cancer and other serious conditions and were distributed nationwide to pharmacies and healthcare facilities. Because these products did not meet strict quality control standards during production, their safety and effectiveness cannot be guaranteed.
The manufacturing deviations could result in products that do not meet their required quality specifications, which may lead to ineffective treatment or unexpected side effects for patients using these critical medications.
Refund for unused product
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.